Rheumatoid arthritis (RA) is a common autoimmune disease where the body's immune system mistakenly attacks the lining of its own joints, causing chronic pain, swelling, and stiffness. While there have ...

More than 18 million people worldwide suffer from rheumatoid arthritis, including nearly 1.5 million Americans. Rheumatoid arthritis is an autoimmune, inflammatory form of arthritis, meaning a ...

Dr. Deane has received grant funding from the Arthritis Foundation, the National Institutes of Health, Boehringer Ingelheim, Gilead and ThermoFisher, and has had consulting/advisory board ...

Rheumatoid arthritis (RA) is a chronic autoimmune condition with symptoms that include pain, stiffness, and swelling in the joints. While medications are the gold standard for RA treatment, many ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but their relative effects on pain, versus inflammation, are less ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Vagus nerve-mediated neuroimmune modulation by electrical stimulation using an implantable device was ...

Rheumatoid arthritis begins years before pain ever appears, and scientists have now mapped the hidden immune battle that unfolds long before symptoms. By studying people with RA-linked antibodies over ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

Getting your Trinity Audio player ready... People who develop rheumatoid arthritis experience changes to their immune systems long before their joints become swollen and painful, suggesting that early ...

Signs of immune system aging appear years before rheumatoid arthritis takes hold, offering new hope for early diagnosis and treatments that could slow or stop the disease before it starts, according ...

Flying high after an FDA approval four months ago to treat generalized myasthenia gravis (gMG), Johnson & Johnson’s much-touted Imaavy (nipocalimab) has taken a hit, coming up short as part of a ...